



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



To,

Date: 14.09.2017

BSE Limited
P.J. Towers
Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited
Bandra-Kurla Complex
Bandra (East)
Mumbai 400051

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.09.2017

Ref: BSE Scrip Code 539287, NSE - ORTINLABSS

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s. Ortin Laboratories Limited held on Thursday, 14.09.2017 at 4:00 p.m. at the registered office of the company at D. No: 1-2-593/29, Ground Floor, Street No.4, GaganMahal Colony, Domalguda, Hyderabad - 500029, Telangana, the following were considered and approved:

1. Un-Audited financial results for the quarter ended 30.06.2017. (Attached)
2. Limited Review Report for the quarter ended 30.06.2017. (Attached)

The meeting concluded at 6.15 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Ortin laboratories Limited

S. Murali Krishna Murthy
Managing Director
DIN: 00540632



Encl: as above



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



ORTIN LABORATORIES LIMITED			
H.NO. 1-2-593/29, STREET NO.4, GAGANMAHAL COLONY,DOMALGUDA,HYDERABAD-500029.			
Statement of Un-Audited Results for the Quarter ended 30.06.2017			
S.No.	Particulars	Amounts in Lakhs	
		For the Quarter ended (30.06.2017)	For the Quarter ended (30.06.2016)
I.	Revenue from Operations	1,133.73	1,226.35
II.	Other Income	34.48	2.90
III.	Total income (I+II)	1,168.21	1,229.25
IV.	Expenses		
	(a) Cost of Materials consumed	681.76	603.98
	(b) Changes in inventories of finished goods, work-in-progress and	(35.25)	93.42
	(c) Employee benefits expense	80.10	72.11
	(d) Finance Cost	88.23	75.75
	(e) Depreciation and amortisation expense	41.92	41.77
	(f) Other expenses	271.91	299.19
	Total Expenses	1,128.67	1,186.22
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	39.54	43.03
VI.	Exceptional Items	-	-
VII	Profit / (Loss) from before tax (V-VI)	39.54	43.03
VIII.	Tax expense		
	Current Tax	20.56	12.37
	Deferred Tax	8.46	(58.62)
IX.	Net Profit / (Loss) after Tax (VII-VIII)	10.52	89.28
X	Other Comprehensive Income		
	Items that will not be reclassified to Profit or Loss	-	-
	Items that will be reclassified to Profit or Loss	-	-
XI	Total Comprehensive Income	10.52	89.28
XII	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,694.04	1,694.04
XIII	Earnings Per Equity Share of face value of Rs.10/- each)		
	a) Basic & Diluted (In Rs.)	0.06	0.53

NOTES:

1

The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.09.2017

2

The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. The Ind-AS Compliant Standardlone Financial results for the corresponding quarter ended June 30, 2016 have been stated in terms of SEBI Circular dated July, 05, 2016. The date of transition is April 01, 2016. There were no impact of transition to be accounted for in opening reserves.



Corp. & Regd. Office : H.No:1-2-593/29, Ground Floor, Street No.4, Gaganmahal Colony, Near Bala Sai Baba Temple Domalguda, Hyderabad - 500 029, Telangana, INDIA. Phone : +91 40 27562055 / +91 40 27567266

website : www.ortinlabsindia.com Email : info@ortinlabsindia.com

CIN : L24110TG1986PLC006885



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY

3 Reconciliation of results between previously reported (referred to as "Previous GAAP") and Ind-AS for the corresponding quarter ended June 30, 2016 is as under;

Particulars	Quartered	Ended
	30.06.2016	
Net Profit/(loss) as Per Indian GAAP		89.28
Recognition & Measurement at Fair Valuation of receivables, expenses / income, amortization & other expenses		-
Investments, - Fair valuation		-
Total Profit / Loss		89.28
Net Profit/(loss) as per Ind AS		89.28

4 The Company is engaged in only one segment viz. "Manufacturing of Pharmaceuticals' and as such there are no separate reportable segments as per Ind AS -108 "Operating Segments"

Station: Hyderabad
Date : 14.09.2017

For Ortin Laboratories Limited

S. MURALI KRISHNA MURTHY
MANAGING DIRECTOR
DIN:00540632





**Limited Review Report on Standalone Financial Results Pursuant to
Clause 33 of Listing Agreement**

Review Report to the Board of Directors of **ORTIN LABORATORIES LIMITED**

1. We have reviewed the unaudited financial results of Ortin Laboratories Limited (the "Company") for the quarter ended June 30th, 2017 which are included in the accompanying "Statement of Unaudited Financial Results for Quarter ended June 30th, 2017. The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 the "Listing Regulations, 2015) read with SEBI circular dated July 5th, 2016, which has been initiated by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Further, the Management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company's opening unaudited Balance Sheet as at April 1st, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act 2013 and other recognised accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 read with SEBI circular dated July 5th, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the following matters:
 - a) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1st, 2017 and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS. The impact of transition has been accounted for in opening reserves and changes thereafter are recognised in other comprehensive income.



E-mail : matheshca@yahoo.co.in



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

- b) We were neither engaged to review, nor have we reviewed the comparative figures including the reconciliation to the Total Comprehensive Income for the quarter ended on June 30, 2016 and accordingly, we do not express any conclusion on the results in the Statement for the quarter ended June 30, 2016 As set out in Note 1 to the Statement, these figures have been furnished by the Management.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the said Part I of the Statement is not prepared, in all material respects, in accordance with applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Clause 33 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14/09/2017



For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS


B. V. RAMANA REDDY
M. No. 026967 Partner